← Back to Search

Psychedelic

DMT for Depression (DMT-Bolus Trial)

Phase 1
Waitlist Available
Led By Deepak D'Souza, MD
Research Sponsored by Deepak C. D'Souza
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Males and females aged 21 to 65 years
Willing to refrain from taking any medications not approved by the study physician
Must not have
Cognitive dysfunction that could interfere with study participation
First degree relatives with a history of psychosis
Timeline
Screening 3 weeks
Treatment Varies
Follow Up time frame: -60 and -30 minutes before dmt administration; 0, +5, +10, +15, +20, +30, +45, +60, and +120 minutes after dmt administration]blood pressure and heart rate will be measured before, during, and after the dosing on each test day.

Summary

This trial aims to study the effects of a substance called dimethyltryptamine (DMT) on people with depression and those without depression. The researchers believe that DMT may help reduce depression symptoms

Who is the study for?
This trial is for individuals with depression, including major depression. It's also open to healthy people as a control group. Participants must meet specific health requirements and be willing to undergo EEG measures and mood assessments.
What is being tested?
The study tests the effects of two doses each of DMT and THC on depression symptoms and brain changes. Researchers will use EEG to track neuroplasticity and psychometric tools to measure mood alterations in participants.
What are the potential side effects?
Possible side effects may include altered sensory experiences, changes in perception or reality, increased heart rate, coordination issues, anxiety, confusion, nausea, or headaches due to the psychoactive nature of DMT and THC.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 21 and 65 years old.
Select...
I am willing to only take medications approved by the study doctor.
Select...
I have been diagnosed with Major Depressive Disorder and am currently having a severe episode.
Select...
I agree not to drive myself to and from the test sessions.
Select...
I've tried at least one antidepressant for 6 weeks without enough improvement.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I do not have any mental health issues that would prevent me from participating.
Select...
I have a close family member with a history of psychosis.
Select...
I have low blood pressure.
Select...
I have never used psychiatric medication for more than 3 months.
Select...
I do not have a family history of serious mental illness.
Select...
I have had a condition where my lymphocytes grow abnormally.
Select...
I have a history of cancer.
Select...
I have never had a psychotic disorder.
Select...
I have a history of mania.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~time frame: -60 and -30 minutes before dmt administration; 0, +5, +10, +15, +20, +30, +45, +60, and +120 minutes after dmt administration]blood pressure and heart rate will be measured before, during, and after the dosing on each test day.
This trial's timeline: 3 weeks for screening, Varies for treatment, and time frame: -60 and -30 minutes before dmt administration; 0, +5, +10, +15, +20, +30, +45, +60, and +120 minutes after dmt administration]blood pressure and heart rate will be measured before, during, and after the dosing on each test day. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Anxiety
Depression
Drug Reinforcing Effects
+5 more
Secondary study objectives
Adequacy of blinding
Psychological Flexibility

Trial Design

5Treatment groups
Active Control
Placebo Group
Group I: 10 mg slow intravenous push (bolus) over 5 minutes and then 0.01 mg/kg/min for 55 minutesActive Control1 Intervention
Low dose DMT
Group II: 14 mg slow intravenous push (bolus) over 5 minutes and then 0.015 mg/kg/min for 55 minutes.Active Control1 Intervention
Medium Dose DMT
Group III: 0.5 mg over 5 minutes and then 2 mg over and 55 minutesActive Control1 Intervention
THC-Medium Dose
Group IV: 0.1 mg slow intravenous push (bolus) over 5 minutes and then I mg over 55 minutesActive Control1 Intervention
Low Dose THC
Group V: PlaceboPlacebo Group4 Interventions

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Deepak C. D'SouzaLead Sponsor
Deepak D'Souza, MDPrincipal InvestigatorYale University
4 Previous Clinical Trials
445 Total Patients Enrolled
1 Trials studying Depression
18 Patients Enrolled for Depression
~40 spots leftby Dec 2027